Ассоц. проф. д.м.н. Nargız Majıdova

ОБРАЗОВАНИЕ И СПЕЦИАЛИЗАЦИЯ

• 2009–2015 — Samsun Ondokuz Mayıs Üniversitesi, Tıp Fakültesi — tıp eğitimi
• 2016–2020 — Samsun Ondokuz Mayıs Üniversitesi — İç Hastalıkları Uzmanlığı
• 2021–2024 — İstanbul Marmara Üniversitesi — Tıbbi Onkoloji Uzmanlığı

ПРОФЕССИОНАЛЬНЫЙ ОПЫТ

• 2016–2020 — Samsun Ondokuz Mayıs Üniversitesi — İç Hastalıkları Uzmanı
• 2020–2021 — VM Medical Park Samsun Hastanesi — İç Hastalıkları Uzmanı
• 2021–2024 — Marmara Üniversitesi, İstanbul — Tıbbi Onkoloji Uzmanı
• 2024 – н.в. — VM Medical Park Maltepe Hastanesi — Tıbbi Onkoloji Uzmanı

ПРОФЕССИОНАЛЬНЫЕ ЧЛЕНСТВА

• Turkish Society of Medical Oncology
• European Society for Medical Oncology (ESMO)
• American Society of Clinical Oncology (ASCO)

Turkish Medical Association

Исследования и публикации

• Majidova N, Demirağ G, Pehlivan Küçük M Aggressive skin metastasis in lung cancer Tuberk Toraks 2018;66(3):249-252
• Majidova N, Yılmaz B, Cengiz Gültekin A. Bilateral testicular metastasis of prostate adenocarcinoma: A case report-Journal of Experimental and Clinical Medicine 2019; 36(2): 63-65; doi: 10.5835/jecm.omu.36.02.006
• Majidova N, Demirağ G An evaluation of the clinical and treatment features of renal cell carcinoma; J Exp Clin Med 2024; 41(2): 294-298
• Majidova N, Simsek F, Biter S, Yaslıkaya S et all Prognostic Factors Associated with Resected Osteosarcoma:Efficacy of Adjuvant Setting, Real-World Experience;  International Journal of Hematology and Oncology; 2024; 34 (1): 20-27
• Majidova N, Seyyar M, Bayraktar D, Dinç G et all Which factors help to determine the long-term response to first-line tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma: A Turkish multi-centre study; Journal Biomolecules and Biomedicine; 2024; 24 (6): 1785–1794
• Majidova N, Kırcalı M F, Guren A K Systemic Inflammation Response Index and Pan-Immune- Inflammation Value: Prognostic Significance in Metastatic Melanoma Journal of Oncological Sciences 2024;10(3):144-9
• Majidova N, Sarı M, Kahvecioğlu F, et all Clinicopathologic Features and Efficacy of Induction Chemotherapy in Nasopharyngeal Carcinoma: Real-World Experience, Oncol Res Treat 2024; 47:360–366
• Majidova N (2023). Yaşlılarda kolorektal kanserde adjuvan tedavi. B. Akagündüz, B. Karabulut (Ed.), Kolorektal Kanserler. İstanbul: İstanbul Tıp Kitapevi.
• Majidova N (2024). Kanser Hastalarının Başvurduğu Geleneksel ve Tamamlayıcı Tedaviler-Tıbbi Onkolog Gözü ile Bakış ve Onkolojik İlaçlarla Etkileşim. İstanbul Akademisyen Yayınevi
• Ozsay O, Karabacak U, Cetin S, Majidova N Is Diabetes Onset at Advanced Age a Sign of Pancreatic Cancer? Annali Italiani Di Chirurgia, 2022 93, 4: 476-480
• Arıkan R, Sağıroğlu Üstün H, Can Demircan, et all Prognostic Significance Of Mucinous Histology In Metastatic Colorectal Cancer Patients Treated With Regorafenib  Journal of Oncologıcal Scıences 2022; 9 (2): 53-61
• Akin Telli T, Bugdayci O, Alan O, Sariyar N, Isik S, Arikan R, Yasar A, Majidova N, et all Impact of Skeletal Muscle Measurements by Chest Computed Tomography on Survival and Postoperative Complications in Patients with Soft Tissue Sarcoma – Nutrition and Cancer  2022 Apr 13:1-9
• Bayoglu İ; Hüseynov J; Topal A; Majidova N; et all PNI as a potential add‑on biomarker to improve the IMDC prognostic score in mRCC patients who received tyrosine kinase inhibitor in the first-line settingJ. Clin. Med. 2023, 12(19), 6420
• Arıkan R, Alkış H, Işık S, Yaşar A, Çelebi A, Majidova N, et all Evaluation of Predictive and Prognostic Importance of Lung Immune Prognostic Index in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy doı: 10.7759/cureus.40548
• Kostek O, Demirel A, Bekir Hacıoğlu M, Tastekin D, Karabulut S, Gündogdu A, Ayhan M, Çelebi A, Majidova N, et all The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing, Journal of Chemotherapy  doi:10.1080/1120009X.2024.2305066
• Guliyev M, Alkan Şen G, Gültürk İ, Majidova N, et all The efects of low HER2 expression on survival in patients with metastatic breast cancer treated with CDK 4/6 inhibitors: a multicenter retrospective study doi:10.1007/s10549-024-07291-0
• Cagri Yildirim H, Kapar C, Koksal B, Seyyar M, Can Sanci P, Guliyev M, Perkin P, Buyukkor M, Yaslikaya S, Majidova N, et all Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study;  Journal of Chemotherapy , doi:10.1080/1120009X.2024.2330835
• Guren K, Kocaaslan E, Agyol Y, Majidova N, et all HER2 exon 20 mutant non-small cell lung cancer with complete remission of intracranial metastases with trastuzumab deruxtecan: a case report; Journal Anti-Cancer Drugs; doi: 10.1097/CAD.0000000000001625
• Akyıldız A, Gultekin M, Yiğit E, Demir E, Majidova N, et all Efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: multicenter study by Turkish Oncology Group; International Journal of Gynecological cancer doi:10.1136/ijgc-2024-005419
• Akyıldız a, Guven D, Majidova N, et all Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG) European Archives of Oto-Rhino-Laryngologyhttps://doi:10.1007/s00405-024-08744-4
• Tascı E, Kutlu Y, Majidova N, et all Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study Expert Opinion on Pharmacotherapy doi:10.1080/14656566.2024.2337261
• Tascı E, Mutlu A, Saylık O, Ölmez Ö, Bilici A, Majidova N, et all Total Neoadjuvant Therapy Versus Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: A Multi-Institutional Real-World Study Cancers 2024, 16(18), 3213; doi: 10.3390/cancers16183213
• Güren A K, Majidova N, et all Efficacy of Combined Bevacizumab and Angiotensin-Converting Enzyme Inhibitors or Angiotensin II type 1 Receptor Blockers in Metastatic Colorectal Cancer Patients; Middle East Journal of Cancer doi: 10.30476/mejc.2024.102063.2071
• Ozkul Ö, Sahin E, Cabuk D, Majidova N, et all The Role of Immune-Inflammation Biomarkers to Predictthe Response of Nivolumab in Second Line Treatment ofAdvanced Stage Non-Small Cell Lung Cancer; EJMI 2024;8(1):58–66
• Akdag G, Alan O, Dogan A, Yıldırım S, Kınıkoğlu O, Majidova N, et all Efficacy and Safety of İxabepilone in Metastatic Breast Cnacer After Multiple Treatments: Analysis Based on Real-World Data; Journal of Oncological Sciences doi: 10.37047/jos.2024-102164
• Kuzan B, Majidova N, Can I, et all Evaluation of sarcopenia-associated survival in breast cancer with computed tomography-based pectoral muscle area measurements; Marmara Medical Journal, 2024, 37 (2) p178; doi: 10.5472/marumj.1484705
• Şimşek F, Majidova N, et all The Prognostic Importance of Clinicopathological Factorsin Patients with Osteosarcoma Who Received NeoadjuvantTherapy; A Single Center Experience; EJMI 2024;8(3):184–192